S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   0.62 (-3.91%)
DOW   0.62 (-3.91%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

OTCMKTS:PPCBPropanc Biopharma Stock Price, Forecast & News

$0.0024
0.00 (-20.00 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range
$0.00
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.00
$3.00
Volume47.34 million shs
Average Volume6.00 million shs
Market Capitalization$113,006.40
P/E RatioN/A
Dividend YieldN/A
Beta2.98
Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. The company's lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. Propanc Biopharma, Inc. has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PPCB
CUSIPN/A
Phone610398820780

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($4.61) per share

Profitability

Net Income$-5,760,000.00

Miscellaneous

Employees1
Market Cap$113,006.40
Next Earnings Date10/20/2020 (Estimated)
OptionableNot Optionable

Receive PPCB News and Ratings via Email

Sign-up to receive the latest news and ratings for PPCB and its competitors with MarketBeat's FREE daily newsletter.

Propanc Biopharma (OTCMKTS:PPCB) Frequently Asked Questions

How has Propanc Biopharma's stock been impacted by COVID-19 (Coronavirus)?

Propanc Biopharma's stock was trading at $0.0449 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PPCB stock has decreased by 94.7% and is now trading at $0.0024. View which stocks have been most impacted by Coronavirus.

When is Propanc Biopharma's next earnings date?

Propanc Biopharma is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020. View our earnings forecast for Propanc Biopharma.

How were Propanc Biopharma's earnings last quarter?

Propanc Biopharma Inc (OTCMKTS:PPCB) issued its earnings results on Friday, May, 15th. The company reported ($0.35) EPS for the quarter. View Propanc Biopharma's earnings history.

Has Propanc Biopharma been receiving favorable news coverage?

Media coverage about PPCB stock has trended somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Propanc Biopharma earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Propanc Biopharma.

Who are some of Propanc Biopharma's key competitors?

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Canopy Growth (CGC), Cronos Group (CRON), Avis Budget Group (CAR), Crispr Therapeutics (CRSP), Insys Therapeutics (INSY), Bed Bath & Beyond (BBBY), Charlotte's Web (CWBHF), Delcath Systems (DCTH), General Electric (GE) and Petroteq Energy (PQEFF).

Who are Propanc Biopharma's key executives?

Propanc Biopharma's management team includes the following people:
  • Mr. James Nathanielsz, Acting Chairman, CEO, CFO, Sec., Treasurer & Director (Age 45)
  • Dr. Julian Norman Kenyon, Chief Scientific Officer & Director (Age 71)
  • Prof. Klaus Kutz, Chief Medical Officer & Member of Scientific Advisory Board

What is Propanc Biopharma's stock symbol?

Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."

How do I buy shares of Propanc Biopharma?

Shares of PPCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Propanc Biopharma's stock price today?

One share of PPCB stock can currently be purchased for approximately $0.00.

How big of a company is Propanc Biopharma?

Propanc Biopharma has a market capitalization of $113,006.40. Propanc Biopharma employs 1 workers across the globe.

What is Propanc Biopharma's official website?

The official website for Propanc Biopharma is www.propanc.com.

How can I contact Propanc Biopharma?

Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The company can be reached via phone at 610398820780 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.